List of Tables
Table 1 Cell and Gene Therapy Landscape
Table 2 Gene Therapy R&D Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 3 Cell and Gene Therapy Landscape
Table 4 Cell and Gene Therapy Landscape
Table 5 Cell and Gene Therapy Landscape
Table 6 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "V" Shaped Recovery
Table 7 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "U" Shaped Recovery
Table 8 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "W" Shaped Recovery
Table 9 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "L" Shaped Recovery
Table 10 Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 11 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 12 Rare Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 13 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 14 Ophthalmic Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 15 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 16 Neurological Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 17 Diabetes Mellitus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 18 Other Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 19 Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 20 Pharmaceutical & Biotechnology Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 21 Non-viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 22 Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 23 Gene Augmentation Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 24 Gene Replacement Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 25 Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 26 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Universities Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Big Pharma Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Global Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 31 North America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 32 North America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 33 North America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 34 North America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 35 North America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 36 U.S. Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 37 Canada Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 38 Europe Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 39 Europe Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 40 Europe Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 41 Europe Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 42 Europe Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 43 Germany Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 44 UK Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 45 France Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 46 Italy Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 47 Spain Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 48 Russia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 49 Rest of Europe Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 50 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 51 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 52 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 53 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 54 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 55 Japan Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 56 China Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 57 India Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 58 Australia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 59 South Korea Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 60 South East Asia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 61 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 62 Latin America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 63 Latin America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 64 Latin America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 65 Latin America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 66 Latin America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 67 Brazil Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 68 Mexico Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 69 Rest of Latin America Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 70 MEA Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 71 MEA Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 72 MEA Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 73 MEA Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 74 MEA Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 75 GCC Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 76 South Africa Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 77 Rest of MEA Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 78 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Astellas Pharma Inc.: Product Benchmarking
Table 80 American Gene Technologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 American Gene Technologies: Product Benchmarking
Table 82 Beacon Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Beacon Therapeutics: Product Benchmarking
Table 84 Beacon Therapeutics: Strategic Outlook
Table 85 Bayer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Bayer: Product Benchmarking
Table 87 Bayer: Strategic Outlook
Table 88 Benitec BioPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Benitec BioPharma: Product Benchmarking
Table 90 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Biogen: Product Benchmarking
Table 92 Biogen: Strategic Outlook
Table 93 Bluebird Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Bluebird Bio: Product Benchmarking
Table 95 Bluebird Bio: Strategic Outlook
Table 96 Bristol Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Bristol Myers Squibb: Product Benchmarking
Table 98 Bristol Myers Squibb: Strategic Outlook
Table 99 Calimmune, Inc. (CSL Behiring): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Calimmune, Inc. (CSL Behiring): Product Benchmarking
Table 101 Calimmune, Inc. (CSL Behiring): Strategic Outlook
Table 102 Cellectis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Cellectis: Product Benchmarking
Table 104 Cellectis: Strategic Outlook
Table 105 GenSight Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 GenSight Biologics: Product Benchmarking
Table 107 Gilead Lifesciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Gilead Lifesciences, Inc.: Product Benchmarking
Table 109 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Novartis AG: Product Benchmarking
Table 111 Novartis AG: Strategic Outlook
Table 112 Orchard Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Orchard Therapeutics: Product Benchmarking
Table 114 Oxford Biomedica: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Oxford Biomedica: Product Benchmarking
Table 116 Oxford Biomedica: Strategic Outlook
Table 117 Pfizer, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Pfizer, Inc.: Product Benchmarking
Table 119 Pfizer, Inc.: Strategic Outlook
Table 120 REGENXBIO Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 REGENXBIO Inc.: Product Benchmarking
Table 122 REGENXBIO Inc.: Strategic Outlook
Table 123 Sangamo Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Sangamo Therapeutics, Inc.: Product Benchmarking
Table 125 Sangamo Therapeutics, Inc.: Strategic Outlook
Table 126 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 127 Sanofi: Product Benchmarking
Table 128 Sanofi: Strategic Outlook
Table 129 Spark Therapeutics (Subsidiary of Roche): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 130 Spark Therapeutics (Subsidiary of Roche): Product Benchmarking
Table 131 Spark Therapeutics (Subsidiary of Roche): Strategic Outlook
Table 132 Takeda Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Takeda Pharmaceuticals: Product Benchmarking
Table 134 Takeda Pharmaceuticals: Strategic Outlook
Table 135 Transgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 Transgene: Product Benchmarking
Table 137 UniQure NV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 138 UniQure NV: Product Benchmarking
Table 139 UniQure NV: Strategic Outlook
Table 140 Voyager Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 141 Voyager Therapeutics: Product Benchmarking
Table 142 Voyager Therapeutics: Strategic Outlook
Table 143 ViGeneron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 144 ViGeneron: Product Benchmarking
Table 145 ViGeneron: Strategic Outlook
Table 146 GQ Bio Therapeutics GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 147 GQ Bio Therapeutics GmbH: Product Benchmarking
Table 148 GQ Bio Therapeutics GmbH: Strategic Outlook
Table 149 OCUGEN, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 150 OCUGEN, INC.: Product Benchmarking
Table 151 OCUGEN, INC.: Strategic Outlook
Table 152 Taysha GTx: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 153 Taysha GTx: Product Benchmarking
Table 154 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 Sarepta Therapeutics, Inc.: Product Benchmarking
Table 156 Sarepta Therapeutics, Inc.: Strategic Outlook
List of Figures
Figure 1 Gene Therapy R&D Market Segmentation
Figure 2 Gene Therapy R&D Market by Disease: Market Attractiveness Index
Figure 3 Gene Therapy R&D Market by Vector: Market Attractiveness Index
Figure 4 Gene Therapy R&D Market by Techniques: Market Attractiveness Index
Figure 5 Gene Therapy R&D Market by Participants: Market Attractiveness Index
Figure 6 Gene Therapy R&D Market Attractiveness Index by Region
Figure 7 Gene Therapy R&D Market: Market Dynamics
Figure 8 Number of Therapies from Preclinical Through Pre-registration till January 2024
Figure 9 Total Number of Deals by Type
Figure 10 Volume and Dollar Value of Series A and Seed Financings for Gene, Cell, & RNA Therapy Companies
Figure 11 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 12 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 13 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 14 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 15 Gene Therapy R&D Market: Porter’s Five Forces Analysis
Figure 16 Gene Therapy R&D Market: PEST Analysis
Figure 17 Gene Therapy R&D Market Attractiveness Index by Disease
Figure 18 Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 19 Gene Therapy R&D Market Share Forecast by Disease, 2024, 2029, 2034 (%)
Figure 20 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 21 Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Rare Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 23 Rare Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 25 Cardiovascular Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Ophthalmic Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 27 Ophthalmic Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 28 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 29 Hematology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Neurological Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 31 Neurological Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 32 Diabetes Mellitus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 33 Diabetes Mellitus Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 34 Other Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 35 Other Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 36 Gene Therapy R&D Market Attractiveness Index by Disease
Figure 37 Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 38 Gene Therapy R&D Market Share Forecast by Vector, 2024, 2029, 2034 (%)
Figure 39 Viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 40 Viral Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Non-viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 42 Non-viral Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Gene Therapy R&D Market Attractiveness Index by Techniques
Figure 44 Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 45 Gene Therapy R&D Market Share Forecast by Techniques, 2024, 2029, 2034 (%)
Figure 46 Gene Augmentation Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 47 Gene Augmentation Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Gene Replacement Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 49 Gene Replacement Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Gene Therapy R&D Market Attractiveness Index by Participants
Figure 51 Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 52 Gene Therapy R&D Market Share Forecast by Participants, 2024, 2029, 2034 (%)
Figure 53 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 54 Small/Medium Pharma & Biotech Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 55 Universities & Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 56 Universities & Research Institutes Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 57 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 58 Hospitals, Government & Public Bodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 59 Big Pharma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 60 Big Pharma Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 61 Gene Therapy R&D Market Forecast by Region 2024, 2029, 2034 (Revenue, CAGR%)
Figure 62 Gene Therapy R&D Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 63 Gene Therapy R&D Market by Region, 2024-2034 (US$ Mn)
Figure 64 North America Gene Therapy R&D Market Attractiveness Index
Figure 65 North America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 66 North America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 67 North America Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 68 North America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 69 North America Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 70 North America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 71 North America Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 72 North America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 73 North America Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 74 North America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 75 North America Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 76 U.S. Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 77 Canada Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 78 Europe Gene Therapy R&D Market Attractiveness Index
Figure 79 Europe Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 80 Europe Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 81 Europe Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 82 Europe Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 83 Europe Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 84 Europe Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 85 Europe Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 86 Europe Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 87 Europe Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 88 Europe Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 89 Europe Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 90 Germany Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 91 UK Fund Raising to 31st October 2023
Figure 92 UK Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 93 France Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 94 Italy Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 95 Spain Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 96 Russia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 97 Rest of Europe Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 98 Asia Pacific Gene Therapy R&D Market Attractiveness Index
Figure 99 Asia Pacific Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 100 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 101 Asia Pacific Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 102 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 103 Asia Pacific Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 104 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 105 Asia Pacific Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 106 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 107 Asia Pacific Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 108 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 109 Asia Pacific Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 110 Japan Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 111 China Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 112 India Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 113 Australia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 114 South Korea Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 115 South East Asia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 116 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 117 Latin America Gene Therapy R&D Market Attractiveness Index
Figure 118 Latin America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 119 Latin America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 120 Latin America Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 121 Latin America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 122 Latin America Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 123 Latin America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 124 Latin America Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 125 Latin America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 126 Latin America Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 127 Latin America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 128 Latin America Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 129 Brazil Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 130 Mexico Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 131 Rest of Latin America Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 132 MEA Gene Therapy R&D Market Attractiveness Index
Figure 133 MEA Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 134 MEA Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 135 MEA Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 136 MEA Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 137 MEA Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 138 MEA Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 139 MEA Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 140 MEA Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 141 MEA Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 142 MEA Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 143 MEA Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 144 GCC Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 145 South Africa Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 146 Rest of MEA Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 147 Astellas Pharma Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 148 Astellas Pharma Inc.: Regional Market Shares (%), 2022
Figure 149 Astellas Pharma Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 150 Beacon Therapeutics: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 151 Beacon Therapeutics: R&D, 2015-2022 (US$ Million, AGR %)
Figure 152 Bayer: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 153 Bayer: Regional Market Shares (%), 2023
Figure 154 Bayer: Business Segment Market Shares, 2023
Figure 155 Bayer: R&D, 2015-2023 (US$ million, AGR %)
Figure 156 Benitec BioPharma: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 157 Benitec BioPharma: R&D, 2015-2023 (US$ Million, AGR %)
Figure 158 Biogen: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 159 Biogen: Regional Market Shares (%), 2022
Figure 160 Biogen: R&D, 2015-2023 (US$ Million, AGR %)
Figure 161 Bluebird Bio: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 162 Bluebird Bio: R&D, 2015-2023 (US$ Million, AGR %)
Figure 163 Bristol Myers Squibb: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 164 Bristol Myers Squibb: Regional Market Shares (%), 2023
Figure 165 Bristol Myers Squibb: R&D, 2015-2023 (US$ Million, AGR %)
Figure 166 Cellectis: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 167 Cellectis: R&D, 2015-2023 (US$ Million, AGR %)
Figure 168 Gilead Lifesciences, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 169 Gilead Lifesciences, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 170 Novartis AG: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 171 Novartis AG: Regional Market Shares (%), 2023
Figure 172 Novartis AG: Business Segment Market Shares, 2023
Figure 173 Novartis AG: R&D, 2015-2023 (US$ million, AGR %)
Figure 174 Oxford Biomedica: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 175 Oxford Biomedica: Regional Market Shares (%), 2023
Figure 176 Pfizer, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 177 Pfizer, Inc.: Regional Market Shares (%), 2023
Figure 178 Pfizer, Inc.: Business Segment Market Shares, 2023
Figure 179 Pfizer, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 180 REGENXBIO Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 181 REGENXBIO Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 182 Sangamo Therapeutics, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 183 Sangamo Therapeutics, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 184 Sanofi: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 185 Sanofi: Regional Market Shares (%), 2023
Figure 186 Sanofi: R&D, 2015-2023 (US$ Million, AGR %)
Figure 187 Takeda Pharmaceuticals: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 188 Takeda Pharmaceuticals: R&D, 2015-2023 (US$ Million, AGR %)
Figure 189 UniQure NV: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 190 UniQure NV: R&D, 2015-2023 (US$ Million, AGR %)
Figure 191 Voyager Therapeutics: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 192 Voyager Therapeutics: R&D, 2015-2023 (US$ Million, AGR %)